Fresenius Kabi Deutschland GmbH
13 products tracked · names used in filings: Fresenius Kabi Deutschland GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Conexxence denosumab | Authorised | 2025-07-18 |
| 🇪🇺 | Bomyntra denosumab | Authorised | 2025-07-17 |
| 🇪🇺 | Otulfi ustekinumab | Authorised | 2024-09-25 |
| 🇪🇺 | Azacitidine Kabi azacitidine | Authorised | 2024-01-05 |
| 🇪🇺 | Tyenne tocilizumab | Authorised | 2023-09-15 |
| 🇪🇺 | Sugammadex Fresenius Kabi sugammadex | Authorised | 2022-07-15 |
| 🇪🇺 | Stimufend pegfilgrastim | Authorised | 2022-03-28 |
| 🇪🇺 | Bortezomib Fresenius Kabi bortezomib | Authorised | 2019-11-14 |
| 🇪🇺 | Kromeya adalimumab | Withdrawn | 2019-04-02 |
| 🇪🇺 | Idacio adalimumab | Authorised | 2019-04-02 |
| 🇪🇺 | Pemetrexed Fresenius Kabi pemetrexed | Authorised | 2016-07-22 |
| 🇪🇺 | Busulfan Fresenius Kabi busulfan | Authorised | 2014-09-22 |
| 🇪🇺 | Docetaxel Kabi docetaxel | Authorised | 2012-05-22 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.